2. Search Result
Search Result
Results for "

competitive noncovalent inhibitor

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

2

Natural
Products

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-117043
    GRL0617
    Maximum Cited Publications
    13 Publications Verification

    		 Deubiquitinase SARS-CoV Infection
    GRL0617 is a selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro), with an IC50 of 0.6 μM and a Ki value of 0.49 μM. GRL0617 also inhibits SARS-CoV with an EC50 of 14.5 μM. GRL0617 can be used for the research of severe acute respiratory syndrome .
    GRL0617
  • HY-155108B
    OATD-02 hydrochloride
    1 Publications Verification

    		 Arginase Cancer
    OATD-02 hydrochloride is the hydrochloride salt form of OATD-02 (HY-155108). OATD-02 hydrochloride an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and Arginase2. OATD-02 hydrochloride is a slow offset inhibitor, blocking intracellular arginases with IC50s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 hydrochloride bolishes tumor immunosuppression induced by both arginases. OATD-02 hydrochloride can be used for melanoma study .
    OATD-02 hydrochloride
  • HY-W012817
    Methylhydroquinone

    		Environmental Pollutants COX Inflammation/Immunology
    Methylhydroquinone is an orally active COX inhibitor with IC50s of 480.7 μM and 52.2 μM for ovine COX-1 and human recombinant COX-2, respectively. Methylhydroquinone has potential DNA damaging effects: 1) inhibiting COX-1 to reduce prostaglandin synthesis and exert anti-inflammatory activity; 2) inducing DNA single-strand breaks. Methylhydroquinone exerts its effects by competitively binding to the active sites of COX-1 (such as Tyr385, Met522) and non-covalent interactions .
    Methylhydroquinone
  • HY-159829
    Direclidine

    NBI-1117568; HTL-0016878

    		 mAChR Neurological Disease
    Direclidine (NBI-1117568, HTL-0016878) is a selective orthosteric agonist targeting the muscarinic acetylcholine M4 receptor, exhibiting very low affinity for M1, M2, M3, and M5 receptors. It binds to the orthosteric site of the M4 receptor in a non-covalent, competitive manner. Direclidine specifically activates the M4 receptor, inhibiting the release of acetylcholine from striatal cholinergic interneurons, thereby regulating the balance of the dopaminergic system and reducing psychiatric symptoms associated with excessive dopamine release. Direclidine can improve symptoms associated with neuropsychiatric disorders and is used in research on schizophrenia and other neuropsychiatric disorders .
    Direclidine
  • HY-133130
    JNJ-42226314
    1 Publications Verification

    		 MAGL Neurological Disease
    JNJ-42226314, a chemical probe, is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .
    JNJ-42226314
  • HY-155108
    OATD-02

    		Arginase Cancer
    OATD-02 is an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and 2. OATD-02 is a slow offset inhibitor, blocking intracellular arginases with IC50s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 abolishes tumor immunosuppression induced by both arginases. OATD-02 can be used for melanoma study .
    OATD-02
  • HY-137191
    CH7233163

    		EGFR Cancer
    CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S. CH7233163 can overcome Osimertinib (HY-15772)-Resistant EGFR-Del19/T790M/C797S mutation. CH7233163 blocks the EGFR phosphorylation in the Del19/T790M/C797S_NIH3T3 cells. CH7233163 has antitumor activities .
    CH7233163
  • HY-10243
    Vaniprevir

    MK-7009

    		 HCV HCV Protease Infection
    Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.
    Vaniprevir
  • HY-169422A
    GSK4418959 (enantiomer)

    IDE275 (enantiomer)

    		 DNA/RNA Synthesis Cancer
    GSK4418959 enantiomer is an enantiomer of GSK4418959 (HY-169422). GSK4418959 (IDE275) is a non-covalent, reversible, selective and orally active WRN helicase inhibitor. GSK4418959 inhibits ATPase and DNA unwinding functions in an ATP-competitive manner. GSK4418959 can be used for the study of microsatellite instability-high (MSI-H) cancer .
    GSK4418959 (enantiomer)
  • HY-177936
    NAE-IN-3

    		NEDD8-activating Enzyme Cancer
    NAE-IN-3 (compound 1) is a potent, selective and non-covalent competitive NEDD8-activating enzyme (NAE) inhibitor (IC50 = 0.8 μM). NAE-IN-3 inhibits NAE by blocking the ATP-binding domain. NAE-IN-3 exhibits selectivity over analogous E1 enzymes UAE and SAE. NAE-IN-3 can be used for cancer research .
    NAE-IN-3
  • HY-149929
    EBL-3183

    		Beta-lactamase Bacterial Infection
    EBL-3183, an indole-2-carboxylate, is a potent metallo-β-lactamase (MBL) inhibitor. EBL-3183 is reversibly binding, non-covalent, competitive NDM-1 inhibitor with a pIC50 of 7.7 .
    EBL-3183
  • HY-156029
    IA1-8H2

    		Phosphatase Cancer
    IA1-8H2 is a non-covalent, non-competitive inhibitor of PHPT1 (IC50: 3.4 μM). IA1-8H2 can be used for research of lung cancer, hepatocarcinoma, and renal cancer .
    IA1-8H2
  • HY-W012817R
    Methylhydroquinone (Standard)

    		COX Reference Standards Others
    Methylhydroquinone (Standard) is the analytical standard of Methylhydroquinone. This product is intended for research and analytical applications. Methylhydroquinone is an orally active COX inhibitor with IC50s of 480.7 μM and 52.2 μM for ovine COX-1 and human recombinant COX-2, respectively. Methylhydroquinone has potential DNA damaging effects: 1) inhibiting COX-1 to reduce prostaglandin synthesis and exert anti-inflammatory activity; 2) inducing DNA single-strand breaks. Methylhydroquinone exerts its effects by competitively binding to the active sites of COX-1 (such as Tyr385, Met522) and non-covalent interactions[1][2].
    Methylhydroquinone (Standard)
  • HY-176219
    Bcl-2-IN-23

    		Bcl-2 Family Apoptosis Necroptosis Cancer
    Bcl-2-IN-23 (compound 5) is a selective inhibitor targeting Bcl-2. The IC50 of Bcl-2-IN-23 in HTB-140, HeLa and SW620 cells is 25.7-33.7 μM. Bcl-2-IN-23 can non-covalently competitively bind to Bcl-2 protein, significantly reduce its expression, and induce late apoptosis and necroptosis of cancer cells. Bcl-2-IN-23 enhances the sensitivity of cancer cells to apoptosis and reduces the release of IL-6 inflammatory factors by disrupting the Bcl-2-mediated mitochondrial apoptosis inhibition pathway. Bcl-2-IN-23 can be used for anti-apoptosis research of malignant tumors such as melanoma, cervical cancer, and colorectal cancer .
    Bcl-2-IN-23
  • HY-182605
    NU6310

    		CDK Cancer
    NU6310 is a non-covalent, ATP-competitive CDK2 inhibitor with an IC50 of 0.16 μM against CDK2. NU6310 can be used for research on cell cycle regulation related to tumors .
    NU6310
  • HY-170399
    SARS-CoV-2 PLpro-IN-1

    		SARS-CoV Virus Protease Infection Cancer
    SARS-CoV-2 PLpro-IN-1 (Compound 85) is a non-covalent and competitive inhibitor of SARS-CoV-2 PLpro with an IC50 of 15.06 μM and a Ki of 22.93 μM. SARS-CoV-2 PLpro-IN-1 inhibits the proliferation of Vero cell with an IC50 of 7.47 μM .
    SARS-CoV-2 PLpro-IN-1
  • HY-173305
    Mpro/PLPro-IN-2

    		SARS-CoV Virus Protease Infection
    Mpro/PLPro-IN-2 (Compound 22l) is a non-covalent competitive dual inhibitor of the papain-like protease and main protease of SARS-CoV-2, with a Ki of 0.2 μM for the papain-like protease and a Ki of 1.1 μM for the main protease . Mpro/PLPro-IN-2 can be used in the research field of anti-SARS-CoV-2 .
    Mpro/PLPro-IN-2
  • HY-181912
    D-DT/MIF-1-IN-1

    		Macrophage migration inhibitory factor (MIF) ERK Cancer
    D-DT/MIF-1-IN-1 (Compound 4h) is a non-competitive, non-covalent inhibitor of MIF-1 and D-DT, with IC50 values of 2.4 μM and 4.0 μM against D-DT, and an IC50 value of 9.8 μM against MIF-1. D-DT/MIF-1-IN-1 inhibits D-DT-induced phosphorylation of ERK and exerts antiproliferative activity in non-small cell lung cancer cells .
    D-DT/MIF-1-IN-1

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: